Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. The forecast total sales of $12.9bn by 2028 underscores the significant impact Leqembi is expected to have on the market.

Compounding 59

Compounding 59

Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028. The forecast total sales of $12.9bn by 2028 underscores the significant impact Leqembi is expected to have on the market.

Compounding 52

Compounding 52

STAT

MARCH 25, 2024

With the lease on its two-building campus on Fan Pier set to expire in 2028, the company is reevaluating its real estate options — and considering leaving its prominent headquarters for another spot in the neighborhood. Now, Vertex may be on the move again. Continue to STAT+ to read the full story…

Drug Development 227

Drug Development 227

STAT

JANUARY 8, 2024

That could come as soon as 2028. The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug.

Immunity 250

Immunity Immunization 250

STAT

SEPTEMBER 28, 2023

The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians. Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives.

Hospitals 319

Hospitals 319

European Pharmaceutical Review

MARCH 20, 2024

million by 2028. percent between 2022-2028, the research found. Based on the research, the US LIMS market is predicted to value $1 billion by 2028. According to a report by Arizton, the Europe laboratory information management system (LIMS) market is expected to reach $912.47 The market is growing at a CAGR of 10.16

92

92

Pharmacy Times

JANUARY 22, 2024

The IQVIA Global Use of Medicines report for 2024 predicts that loss of brand exclusivity will negatively impact global market growth.

58

58

BioPharma Dive

JANUARY 29, 2024

An under-the-skin Opdivo shot produced similar results to an intravenous formulation in kidney cancer, giving Bristol Myers a chance at sustaining sales past a key patent expiration in 2028.

68

68

Pharmaceutical Commerce

JANUARY 18, 2024

The predicted value is largely driven by manufacturers' prioritization of brand protection.

52

52

BioPharma Dive

APRIL 20, 2023

With the court victory, the biotech giant could stave off a set of generic competitors for the top-selling drug until 2028.

101

101

PharmExec

JULY 18, 2023

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

52

52

European Pharmaceutical Review

DECEMBER 4, 2023

billion by 2028, growing at a CAGR of 6.8 percent between 2023 to 2028. Moreover, the non-toxic nature of organic chemicals is expected to drive the organic chemicals sectors, ultimately boosting the pharmaceutical excipient market in the forecast period (2023 to 2028).

Pharmaceutical Companies 88

Pharmaceutical Companies Pharmaceutical Companies 88

Pharmaceutical Technology

JANUARY 15, 2024

MSD’s blockbuster immunotherapy, set to lose patent protection in 2028, secures third FDA approval in cervical cancer.

59

59

Pharmaceutical Commerce

SEPTEMBER 25, 2023

This would signify an 8.3% CAGR over the next five years.

52

52

Pharmaceutical Technology

JANUARY 9, 2024

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

52

52

STAT

JANUARY 25, 2023

The data is a setback for Merck, which has been working to expand use of Keytruda, which has powered its growth for years but will lose exclusivity in 2028. The drug was being tested in combination with androgen deprivation therapy and Xtandi in patients with hormone-sensitive prostate cancer that has spread to other parts of the body.

189

189

The Pharmacist

JUNE 30, 2023

Training places for pharmacists will be expanded by almost a third (29%) by 2028/29, NHS England has announced today within its new workforce plan. And the ambition is to increase training places for the profession by nearly 50% – to around 5,000 places per year – by 2031/32, it said.

70

70

Pharmaceutical Technology

JANUARY 30, 2023

These are forecast to generate $264 billion in sales between 2021 and 2028. The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

APRIL 15, 2024

The new investment in the Holly Springs facility will “add 8 x 20,000 L mammalian cell culture bioreactors by 2028, to the already planned 8 x 20,000 L for bulk drug substance as part of the initial investment”.

80

80

Express Pharma

APRIL 25, 2024

As Lynparza’s patent protection in the US market will expire in 2028, there is an anticipated downshift in sales post-patent expiry through generic erosion.

Chemotherapy 80

Chemotherapy 80

European Pharmaceutical Review

NOVEMBER 24, 2023

These activities are expected to be completed incrementally between 2026 to 2028, the company stated. While the current production facility in Chartres, France, employ around 1,600 people, once the new multi-product facilities are in operation, over 500 new jobs will be created to manage continuous production activities.

Pharmaceutical Manufacturing 95

Pharmaceutical Manufacturing Packaging 95

European Pharmaceutical Review

MARCH 14, 2024

billion by 2028, based on data from Evaluate Pharma. Prior to this new facility expansion, SK bioscience highlighted that in 2021, L HOUSE was the first domestic vaccine manufacturing facility to achieve EU-GMP certification from the European Medicines Agency (EMA).

Vaccines 81

Vaccines 81

Pharmacy Times

AUGUST 18, 2022

Study results show a compound annual growth rate of 5.2% billion in revenue in 2021.

Compounding 26

Compounding 26

European Pharmaceutical Review

DECEMBER 19, 2023

The workplan, which runs until 2028, will help the European medicines regulatory network (EMRN) embrace the opportunities of AI for personal productivity, automating processes and systems, increasing insights into data and supporting more robust decision-making to benefit public and animal health.

Packaging 89

Packaging Documentation 89

Express Pharma

NOVEMBER 27, 2023

The construction projects have now been initiated and will gradually be finalised from 2026 to 2028. The investment is expected to create more than 500 new jobs to run production activities 24/7 when the construction is completed, and the facilities are finalised.

91

91

Pharmaceutical Technology

JANUARY 25, 2023

Despite this, Spikevax vaccine market share is expected to decline from 30% in 2022 to just 16% by the end of 2028. The therapeutic is expected to be a strong entrant in late 2023, with forecast sales of $2.5bn in 2028. One such therapeutic is PBI-0451, which is currently under development by Pardes Biosciences.

Vaccines 59

Vaccines 59

European Pharmaceutical Review

OCTOBER 16, 2023

The ADC market is expected to grow at a compound annual growth rate (CAGR) of 20 percent between 2023 and 2028, the contract development and manufacturing organisation (CDMO) highlighted. Enhancing manufacturing capabilities The bioconjugates market is currently valued at $33 billion according to research by Lonza.

Compounding 92

Compounding 92

Express Pharma

SEPTEMBER 27, 2023

million in 2028. .; with over 15,000 US health care providers, representing 88% of total health care providers in dermatology, having prescribed Winlevi to date (per IQVIA MAT June 2023). The EU acne market is projected to grow from $928.7 million in 2021 to $1,297.0

94

94

Express Pharma

APRIL 22, 2024

These advancements aim to mitigate the impact of the upcoming patent loss of exclusivity for GSK’s HIV blockbuster drug, Dolutegravir, starting in 2028. Last year, GSK obtained approvals for four major products: Arexvy RSV vaccine, Apretude for HIV prevention, Ojjaara for myelofibrosis and Jemperli for endometrial cancer.

Drug Pricing 96

Drug Pricing Diabetes Vaccines 96

Express Pharma

OCTOBER 20, 2023

Under an agreement with the government, the drug will also stay free of charge for patients insured under the Medicare and Medicaid programs through the end of 2024, and to uninsured and underinsured patients through 2028.

Drug Pricing 91

Drug Pricing Vaccines 91

pharmaphorum

APRIL 20, 2021

billion by 2028. billion in sales in 2028. Analyst Philippa Salter of GlobalData recently predicted that Kesimpta’s convenience will make it a sought-after option for RMS patients, driving global sales to $3.3 While it requires a clinic visit, Ocrevus only has to be administered twice a year.

Hospitals 111

Hospitals Documentation 111

PharmaShots

MAY 2, 2023

The US FDA was granted the expanded conditional approval authority in the Animal Drug User Fee Act of 2018 with the program planned to sunset in 2028 The efficacy of molidustat oral suspension had been established based on the results of a study conducted in 2 phases in 23 cats aged 4-17yrs.

Vaccines 45

Vaccines 45

Express Pharma

JULY 5, 2023

The patent expiry of Amneal’s Rytary, an oral ER capsule formulation of levodopa, is anticipated in 2028, which will inevitably shrink its sales. Although the drugs are common in PD, the formulation is just novel enough to require further due diligence by the agency.

88

88

PharmaShots

MAY 19, 2023

in quarterly installments during 2024 along with royalties from 2025 to 2028 based on net revenues in the US from Iluvien & Yutiq. Shots: EyePoint to receive $75M up front, $7.5M EyePoint will transfer & assign to Alimera certain assets & certain contracts with third parties related to Yutiq incl.

40

40

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Novo Nordisk reported an 18.2%

Diabetes 52

Diabetes Vaccines Drug Pricing 52

Express Pharma

FEBRUARY 19, 2024

Thomas Wales, Oncology Analyst at GlobalData, comments, “While the CRC market will see steady growth throughout the forecast period, the patent expiry of MSD’s popular immunotherapy Keytruda (pembrolizumab) in 2028 is expected to cause some contraction in the market.

Chemotherapy 99

Chemotherapy 99

European Pharmaceutical Review

JUNE 28, 2023

The treatment is expected to launch in 2028 in the US, EU, and Japan. Data from the ROSE 2 trials suggests that obicetrapib in combination with ezetimibe has the potential to be used in patients who are unable to achieve sufficient LDL-cholesterol lowering with other available lipid-lowering medications,” Dr Mohammad commented.

77

77